查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1192997

糖尿病藥物市場：副產品（注射劑、口服糖尿病藥物）：2020-2030 年全球機會分析和行業預測

Diabetes Therapeutics Market By Product (Injectables, Oral antidiabetic Drugs): Global Opportunity Analysis and Industry Forecast, 2020-2030
出版日期: | 出版商: Allied Market Research | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

2020 年全球糖尿病藥物市場價值 1180.633 億美元，從 2021 年到 2030 年以 10.4% 的複合年增長率增長，預計到 2030 年將達到 3179.15 億美元

糖尿病是一種血糖水平異常的慢性代謝性疾病。 糖尿病藥物是糖尿病患者用來維持體內血糖水平的藥物。

由於糖尿病、高肥胖、久坐不動的生活方式和其他慢性病的患病率上升，預計全球糖尿病藥物市場在不久的將來將出現顯著增長。 例如，根據國際糖尿病聯合會 (IDF) 糖尿病地圖集，到 2021 年將有大約 5.37 億成年人（20-79 歲）患有糖尿病。 此外，不斷增長的老年人口導致了糖尿病藥物市場的增長。 然而，抗糖尿病藥物的副作用阻礙了預測期內的市場增長。 相反，增加糖尿病領域研發活動的資金預計將為市場參與者提供有利可圖的機會。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • COVID-19 影響分析

第 4 章糖尿病藥物市場：按產品分類

  • 概覽
    • 市場規模和預測
  • 注射
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 口服降糖藥
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 5 章糖尿病藥物市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機遇
    • 北美市場規模和預測：按產品
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機會
    • 歐洲市場規模和預測：按產品
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲地區
  • 亞太地區
    • 主要趨勢和機會
    • 亞太市場規模和預測：按產品
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機會
    • LAMEA 市場規模和預測：按產品
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他拉美地區

第6章業務條件

  • 簡介
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第七章公司簡介

  • ASTRAZENECA PLC
  • BOEHRINGER INGELHEIM GMBH
  • ELI LILLY AND COMPANY
  • GLAXOSMITHKLINE PLC
  • NOVARTIS AG
  • NOVO NORDISK
  • SANOFI S.A.
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • johnson and johnson md&d
  • MERCK and CO., INC.
Product Code: A03202

The global diabetes therapeutics market was valued at $118,063.3 million in 2020, and is projected to reach $317,915 million by 2030, registering a CAGR of 10.4% from 2021 to 2030. Diabetes is a chronic metabolic disorder in which there are abnormalities in blood glucose levels. Diabetes therapeutics are drugs used by diabetic patients to conserve the blood glucose levels in the body.

The global diabetes therapeutics market is expected to register substantial growth in the near future, owing to rise in prevalence of diabetes, high obesity, sedentary lifestyles, and other chronic conditions. For instance, according to International Diabetes Federation (IDF),Diabetes Atlas, in 2021, approximately 537 million adults (20-79 years of age) were living with diabetes.  Furthermore, rise in geriatric population led to an increase in growth of diabetes therapeutics market. However, side effects caused by anti-diabetes medication hamper the market growth during the forecast period. Conversely, increase in funding for R&D activities in diabetes sector is expected to offer remunerative opportunities for market players.

The diabetes therapeutics market is segmented into product and region. By product, the market is categorized into injectables and oral-antidiabetic drugs (OAD). By region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, Taiwan, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players operating in the global diabetes therapeutics market include Astrazeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Glaxosmithkline Plc., Johnson & Johnson, Merck & Co., Inc., Novartis Ag ,Novo Nordisk, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of the global diabetes therapeutics market size along with the current trends and future estimations to elucidate the future investment pockets.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of the region helps to understand the regional market, facilitate strategic business planning, and determine prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global diabetes therapeutics market growth.

Key Market Segments

By Product

  • Injectables
  • Oral antidiabetic Drugs

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest Of Asia Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • ASTRAZENECA PLC
    • BOEHRINGER INGELHEIM GMBH
    • ELI LILLY AND COMPANY
    • GLAXOSMITHKLINE PLC
    • NOVARTIS AG
    • NOVO NORDISK
    • SANOFI S.A.
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • johnson and johnson md&d
    • MERCK and CO., INC.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: DIABETES THERAPEUTICS MARKET, BY PRODUCT

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Injectables
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Oral antidiabetic Drugs
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country

CHAPTER 5: DIABETES THERAPEUTICS MARKET, BY REGION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 North America
    • 5.2.1 Key trends and opportunities
    • 5.2.2 North America Market size and forecast, by Product
    • 5.2.3 North America Market size and forecast, by country
      • 5.2.3.1 U.S.
      • 5.2.3.1.1 Market size and forecast, by Product
      • 5.2.3.2 Canada
      • 5.2.3.2.1 Market size and forecast, by Product
      • 5.2.3.3 Mexico
      • 5.2.3.3.1 Market size and forecast, by Product
  • 5.3 Europe
    • 5.3.1 Key trends and opportunities
    • 5.3.2 Europe Market size and forecast, by Product
    • 5.3.3 Europe Market size and forecast, by country
      • 5.3.3.1 Germany
      • 5.3.3.1.1 Market size and forecast, by Product
      • 5.3.3.2 France
      • 5.3.3.2.1 Market size and forecast, by Product
      • 5.3.3.3 United Kingdom
      • 5.3.3.3.1 Market size and forecast, by Product
      • 5.3.3.4 Italy
      • 5.3.3.4.1 Market size and forecast, by Product
      • 5.3.3.5 Spain
      • 5.3.3.5.1 Market size and forecast, by Product
      • 5.3.3.6 Rest of Europe
      • 5.3.3.6.1 Market size and forecast, by Product
  • 5.4 Asia-Pacific
    • 5.4.1 Key trends and opportunities
    • 5.4.2 Asia-Pacific Market size and forecast, by Product
    • 5.4.3 Asia-Pacific Market size and forecast, by country
      • 5.4.3.1 China
      • 5.4.3.1.1 Market size and forecast, by Product
      • 5.4.3.2 Japan
      • 5.4.3.2.1 Market size and forecast, by Product
      • 5.4.3.3 India
      • 5.4.3.3.1 Market size and forecast, by Product
      • 5.4.3.4 Australia
      • 5.4.3.4.1 Market size and forecast, by Product
      • 5.4.3.5 Rest Of Asia Pacific
      • 5.4.3.5.1 Market size and forecast, by Product
  • 5.5 LAMEA
    • 5.5.1 Key trends and opportunities
    • 5.5.2 LAMEA Market size and forecast, by Product
    • 5.5.3 LAMEA Market size and forecast, by country
      • 5.5.3.1 Brazil
      • 5.5.3.1.1 Market size and forecast, by Product
      • 5.5.3.2 Saudi Arabia
      • 5.5.3.2.1 Market size and forecast, by Product
      • 5.5.3.3 South Africa
      • 5.5.3.3.1 Market size and forecast, by Product
      • 5.5.3.4 Rest of LAMEA
      • 5.5.3.4.1 Market size and forecast, by Product

CHAPTER 6: COMPANY LANDSCAPE

  • 6.1. Introduction
  • 6.2. Top winning strategies
  • 6.3. Product Mapping of Top 10 Player
  • 6.4. Competitive Dashboard
  • 6.5. Competitive Heatmap
  • 6.6. Key developments

CHAPTER 7: COMPANY PROFILES

  • 7.1 ASTRAZENECA PLC
    • 7.1.1 Company overview
    • 7.1.2 Company snapshot
    • 7.1.3 Operating business segments
    • 7.1.4 Product portfolio
    • 7.1.5 Business performance
    • 7.1.6 Key strategic moves and developments
  • 7.2 BOEHRINGER INGELHEIM GMBH
    • 7.2.1 Company overview
    • 7.2.2 Company snapshot
    • 7.2.3 Operating business segments
    • 7.2.4 Product portfolio
    • 7.2.5 Business performance
    • 7.2.6 Key strategic moves and developments
  • 7.3 ELI LILLY AND COMPANY
    • 7.3.1 Company overview
    • 7.3.2 Company snapshot
    • 7.3.3 Operating business segments
    • 7.3.4 Product portfolio
    • 7.3.5 Business performance
    • 7.3.6 Key strategic moves and developments
  • 7.4 GLAXOSMITHKLINE PLC
    • 7.4.1 Company overview
    • 7.4.2 Company snapshot
    • 7.4.3 Operating business segments
    • 7.4.4 Product portfolio
    • 7.4.5 Business performance
    • 7.4.6 Key strategic moves and developments
  • 7.5 NOVARTIS AG
    • 7.5.1 Company overview
    • 7.5.2 Company snapshot
    • 7.5.3 Operating business segments
    • 7.5.4 Product portfolio
    • 7.5.5 Business performance
    • 7.5.6 Key strategic moves and developments
  • 7.6 NOVO NORDISK
    • 7.6.1 Company overview
    • 7.6.2 Company snapshot
    • 7.6.3 Operating business segments
    • 7.6.4 Product portfolio
    • 7.6.5 Business performance
    • 7.6.6 Key strategic moves and developments
  • 7.7 SANOFI S.A.
    • 7.7.1 Company overview
    • 7.7.2 Company snapshot
    • 7.7.3 Operating business segments
    • 7.7.4 Product portfolio
    • 7.7.5 Business performance
    • 7.7.6 Key strategic moves and developments
  • 7.8 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 7.8.1 Company overview
    • 7.8.2 Company snapshot
    • 7.8.3 Operating business segments
    • 7.8.4 Product portfolio
    • 7.8.5 Business performance
    • 7.8.6 Key strategic moves and developments
  • 7.9 johnson and johnson md&d
    • 7.9.1 Company overview
    • 7.9.2 Company snapshot
    • 7.9.3 Operating business segments
    • 7.9.4 Product portfolio
    • 7.9.5 Business performance
    • 7.9.6 Key strategic moves and developments
  • 7.10 MERCK and CO., INC.
    • 7.10.1 Company overview
    • 7.10.2 Company snapshot
    • 7.10.3 Operating business segments
    • 7.10.4 Product portfolio
    • 7.10.5 Business performance
    • 7.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 2. DIABETES THERAPEUTICS MARKET REVENUE, FOR INJECTABLES, BY REGION , 2020-2030,($MILLION)
  • TABLE 3. DIABETES THERAPEUTICS MARKET INJECTABLES BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 4. DIABETES THERAPEUTICS MARKET REVENUE, FOR ORAL ANTIDIABETIC DRUGS, BY REGION , 2020-2030,($MILLION)
  • TABLE 5. DIABETES THERAPEUTICS MARKET ORAL ANTIDIABETIC DRUGS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 6. DIABETES THERAPEUTICS MARKET, BY REGION, 2020-2030,($MILLION)
  • TABLE 7. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 8. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 9. U.S. DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 10. CANADA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 11. MEXICO DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 12. EUROPE DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 13. EUROPE DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 14. GERMANY DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 15. FRANCE DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 16. UNITED KINGDOM DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 17. ITALY DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 18. SPAIN DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 19. REST OF EUROPE DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 20. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 21. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 22. CHINA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 23. JAPAN DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 24. INDIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 25. AUSTRALIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 26. REST OF ASIA PACIFIC DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 27. LAMEA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 28. LAMEA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 29. BRAZIL DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 30. SAUDI ARABIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 31. SOUTH AFRICA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 32. REST OF LAMEA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 33.ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 34.ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 35.ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 36.ASTRAZENECA PLC: NET SALES,
  • TABLE 37.ASTRAZENECA PLC: KEY STRATERGIES
  • TABLE 38.BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
  • TABLE 39.BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
  • TABLE 40.BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
  • TABLE 41.BOEHRINGER INGELHEIM GMBH: NET SALES,
  • TABLE 42.BOEHRINGER INGELHEIM GMBH: KEY STRATERGIES
  • TABLE 43.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 44.ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 45.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 46.ELI LILLY AND COMPANY: NET SALES,
  • TABLE 47.ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 48.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 49.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 50.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 51.GLAXOSMITHKLINE PLC: NET SALES,
  • TABLE 52.GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 53.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 54.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 55.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 56.NOVARTIS AG: NET SALES,
  • TABLE 57.NOVARTIS AG: KEY STRATERGIES
  • TABLE 58.NOVO NORDISK: COMPANY SNAPSHOT
  • TABLE 59.NOVO NORDISK: OPERATING SEGMENTS
  • TABLE 60.NOVO NORDISK: PRODUCT PORTFOLIO
  • TABLE 61.NOVO NORDISK: NET SALES,
  • TABLE 62.NOVO NORDISK: KEY STRATERGIES
  • TABLE 63.SANOFI S.A.: COMPANY SNAPSHOT
  • TABLE 64.SANOFI S.A.: OPERATING SEGMENTS
  • TABLE 65.SANOFI S.A.: PRODUCT PORTFOLIO
  • TABLE 66.SANOFI S.A.: NET SALES,
  • TABLE 67.SANOFI S.A.: KEY STRATERGIES
  • TABLE 68.TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 69.TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS
  • TABLE 70.TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 71.TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES,
  • TABLE 72.TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES
  • TABLE 73.JOHNSON AND JOHNSON MD&D: COMPANY SNAPSHOT
  • TABLE 74.JOHNSON AND JOHNSON MD&D: OPERATING SEGMENTS
  • TABLE 75.JOHNSON AND JOHNSON MD&D: PRODUCT PORTFOLIO
  • TABLE 76.JOHNSON AND JOHNSON MD&D: NET SALES,
  • TABLE 77.JOHNSON AND JOHNSON MD&D: KEY STRATERGIES
  • TABLE 78.MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 79.MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 80.MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 81.MERCK AND CO., INC.: NET SALES,
  • TABLE 82.MERCK AND CO., INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.DIABETES THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 2.DIABETES THERAPEUTICS MARKET,2020-2030
  • FIGURE 3.DIABETES THERAPEUTICS MARKET,2020-2030
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.DIABETES THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.DIABETES THERAPEUTICS MARKET,BY PRODUCT,2020(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INJECTABLES DIABETES THERAPEUTICS MARKET,2020-2030(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ORAL ANTIDIABETIC DRUGS DIABETES THERAPEUTICS MARKET,2020-2030(%)
  • FIGURE 15.DIABETES THERAPEUTICS MARKET BY REGION,2020
  • FIGURE 16.U.S. DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 17.CANADA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 18.MEXICO DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 19.GERMANY DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 20.FRANCE DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 21.UNITED KINGDOM DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 22.ITALY DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 23.SPAIN DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 24.REST OF EUROPE DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 25.CHINA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 26.JAPAN DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 27.INDIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 28.AUSTRALIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 29.REST OF ASIA PACIFIC DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 30.BRAZIL DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 31.SAUDI ARABIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 32.SOUTH AFRICA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 33.REST OF LAMEA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 34. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 35. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 36. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 37.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 38.COMPETITIVE DASHBOARD
  • FIGURE 39.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 40.ASTRAZENECA PLC.: NET SALES ,($MILLION)
  • FIGURE 41.BOEHRINGER INGELHEIM GMBH.: NET SALES ,($MILLION)
  • FIGURE 42.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
  • FIGURE 43.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
  • FIGURE 44.NOVARTIS AG.: NET SALES ,($MILLION)
  • FIGURE 45.NOVO NORDISK.: NET SALES ,($MILLION)
  • FIGURE 46.SANOFI S.A..: NET SALES ,($MILLION)
  • FIGURE 47.TAKEDA PHARMACEUTICAL COMPANY LIMITED.: NET SALES ,($MILLION)
  • FIGURE 48.JOHNSON AND JOHNSON MD&D.: NET SALES ,($MILLION)
  • FIGURE 49.MERCK AND CO., INC..: NET SALES ,($MILLION)